Infant Bacterial Therapeutics AB · Healthcare · Sweden
High risk. 8 critical or high findings in GDPR outside view, SSL/TLS and 2 other checks.
Infant Bacterial Therapeutics AB (IBT) is a specialized biopharmaceutical company focused on developing medicines targeting diseases in premature infants and those caused by antibiotic-resistant bacteria. The company emphasizes regulatory compliance with agencies such as the FDA and EMA and conducts clinical studies like 'The Connection Study' to validate its New Biological Entities. The website targets healthcare professionals, investors, and families, providing detailed press releases, investor relations content, and scientific pipeline information. The business operates primarily in Sweden and maintains a small company profile with a clear niche in neonatal healthcare. Technically, the website is built on WordPress with common plugins such as Contact Form 7 and MFN WP Plugin for subscription management. The site uses jQuery 1.9.1 and loads resources from trusted external domains. Performance and mobile optimization are moderate to good, though accessibility features are basic. SEO is implemented at a basic level with meta tags and structured navigation. From a security perspective, the site enforces HTTPS with good SSL configuration but lacks several important security headers. No exposed sensitive data or vulnerabilities were detected in the HTML content. The use of an outdated jQuery version presents a moderate risk. Privacy compliance is partially met with published privacy and cookie policies, but no active cookie consent mechanism is implemented. Contact information is limited to an email address and contact forms, with no phone numbers or physical addresses disclosed. Overall, IBT's website demonstrates a professional and trustworthy online presence with room for improvement in security headers, privacy consent mechanisms, and updating third-party libraries. The WHOIS data aligns well with the business claims, supporting legitimacy. The site is accessible without WAF or blocking mechanisms, enabling full content analysis.
Scanned
NIS2 Art. 21(2)
This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.
GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.
8 findings rated critical or high. Fix these first.
These are the privacy signals visitors and data protection authorities look for under GDPR.
GDPR requires appropriate security measures for personal data
What to do: Implement SSL/TLS certificate for HTTPS
GDPR requires explicit consent for non-essential cookies
What to do: Implement a cookie consent banner that appears on first visit
TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.
Website does not use HTTPS encryption, making all data transmission vulnerable to interception
What to do: Implement SSL/TLS certificate and redirect all HTTP traffic to HTTPS
Services reachable from the internet are the first thing attackers probe. Anything open that does not need to be should be closed.
Port 3306 (MySQL) is publicly accessible - MySQL - Database server
What to do: Immediately restrict access to MySQL using firewall or VPN
Port 21 (FTP) is publicly accessible - FTP - Often unencrypted file transfer
What to do: Consider restricting access to FTP or implementing strong authentication
Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.
Forces HTTPS connections
What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"
Prevents clickjacking attacks
What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"
Controls resources the browser is allowed to load
What to do: Implement a Content-Security-Policy appropriate for your application
Need hands-on remediation? Email guard@offseq.com
This scan found 24 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.
€25per month
Email alerts on material changes and an exportable JSON history of every change.
Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.
€39.90one-time
Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.
Each check with its score, findings and the evidence it collected.
The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.
Counted in this score
Not counted
Findings that cap the score at 49
Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.
Partial scans
When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.
Risk levels
Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.
Leaked records that mention ibtherapeutics.com, from OffSeq Breach.
No leaked records found
Breach holds no records for ibtherapeutics.com right now. New leaks arrive continuously, so monitoring on Breach alerts you if that changes.
Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.
Automated reading of the public site. Ratings are indicative.
Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.
Retrieved 2026-10-25
Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.
Reviews of this site
Share your experience with ibtherapeutics.com. Every review is verified by email and published after moderation.
Community rating
No published reviews yet. Be the first to review ibtherapeutics.com.